Actinium Pharmaceuticals, Inc.

ATNM

Explore Our Financial Data > Companies > Actinium Pharmaceuticals, Inc.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
ATNM
CIK0001388320
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address100 PARK AVE., 23RD FLOOR, NEW YORK, NY, 10017
Website actiniumpharma.com
Phone(646) 677-3870
CEOSandesh Seth
Employees30

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
RevenueN/A
Pre-Tax Income$-45.51 million
Net Income$-45.51 million
Net Income to Common$-45.51 million
EPS$-1.47
View All
Balance Sheet
Cash$65.32 million
Assets$68.65 million
Liabilities$42.95 million
Common Equity$25.69 million
Liabilities & Equity$68.65 million
View All
Cash Flow Statement
Net Income$-45.51 million
Cash From Operating Activities$-33.27 million
Cash From Investing ActivitiesN/A
Cash From Financing Activities$14.55 million
Change in Cash$-18.72 million
View All
Calculations
NOPAT$-34.41 million
EBITDA$-48.98 million
Price to EarningsN/A
Price to Book$1.75
ROE-130.87%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today reported new preclinical data from its first-in-class, non-PSMA targeting radiotherapy prostate cancer candidate ATNM-400, that leverages the potent alpha-particle emitter Actinium-225 (Ac-225) isotope, at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) annual meeting being held June 21st – 24th, 2025, in New Orleans, Louisiana. The data prese

Article Link

Life Sciences Investor Forum: Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and 12th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor

Article Link

Life Sciences Investor Forum Agenda Announced for June 11th-12th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE It is recommended that investors pre-register an

Article Link

Actinium: Q1 Earnings Snapshot

NEW YORK (AP) — Actinium Pharmaceuticals Inc. ATNM) on Friday reported a loss of $15.9 million in its first quarter. On a per-share basis, the New York-based company said it had a loss of 51 cents.

Article Link

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that the first patient was enrolled on the trial studying Iomab-ACT targeted conditioning with a commercial CAR-T therapy at the University of Texas Southwestern Medical Center (UTSW) (NCT06768905). Initial clinical data from this trial is expected in the second half of 2025. Actinium is developing Iomab-ACT as a targeted radiotherapy conditioni

Article Link